SATB2 and inflammatory bowel disease: In a recent study investigating CRCs associated with inflammatory bowel diseases (either Crohn’s disease or ulcerative colitis), the authors found that only 43% of colitis-associated carcinomas expressed SATB2, compared to 91% sporadic CRCs [33].